AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Sponsor

Tianjin Medical University Cancer Institute and Hospital (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT05678933

Collaborator

(none)

200

Enrollment

Location

Arms

Anticipated Duration (Months)

2.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.

Condition or Disease	Intervention/Treatment	Phase
Peripheral T-cell Lymphoma Targeted Therapy	Drug: Azacitidine Drug: Chidamide Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

200 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Azacitidine and Chidamide Combined With CHOP (AC-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma With T-follicular Helper Phenotype (PTCL-TFH)

Anticipated Study Start Date :

Jan 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2027

Anticipated Study Completion Date :

Dec 1, 2029

Arms and Interventions

Arm	Intervention/Treatment
Experimental: AC-CHOP Azacitidine administered IV at day 1-5 and Chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)	Drug: Azacitidine Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle. Drug: Chidamide Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle. Drug: Cyclophosphamide Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: Epirubicin Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle. Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Active Comparator: CHOP CHOP administered every 3 weeks for 6 cycles.	Drug: Cyclophosphamide Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: Epirubicin Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle. Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle. Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.

Arm

Intervention/Treatment

Experimental: AC-CHOP

Azacitidine administered IV at day 1-5 and Chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)

Drug: Azacitidine

Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.

Drug: Chidamide

Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.

Drug: Cyclophosphamide

Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Drug: Epirubicin

Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Drug: Vincristine

Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.

Drug: Prednisone

Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.

Active Comparator: CHOP

CHOP administered every 3 weeks for 6 cycles.

Drug: Cyclophosphamide

Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Drug: Epirubicin

Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Drug: Vincristine

Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.

Drug: Prednisone

Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.

Outcome Measures

Primary Outcome Measures

Progression-free survival (PFS) [Up to 1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must satisfy all following criteria to be enrolled in the study:

Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
Males and females of 18 years of age to 70 years of age.
ECOG performance status 0, 1 or 2
Patients with histologically proven peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH); the following subtypes as defined by the WHO classification (5th) may be included, whatever the Ann Arbor stage (I - IV):

i.Angioimmunoblastic T-cell lymphoma ii. peripheral T-cell lymphoma of follicular type

Nodal and extra-nodal peripheral T cell lymphoma with follicular helper T cell phenotype

Previously received no treatment for PTCL, including chemotherapy, targeted therapy, immunotherapy, local radiotherapy for lymphoma (except for relieving tumor-related symptoms), surgical treatment (except for tumor or pathological tissue biopsy)
Life expectancy of ≥ 90 days (3 months)
At least one evaluable or measurable lesion that meets Lugano2014 criteria: lymph node lesions, which are measurable > 1.5 cm, and non-lymph node lesions, which are measurable>1.0 cm
Female and males patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 12 month thereafter
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, Platelet count ≥ 80 x 109/L, Haemoglobin ≥ 90g/L
Serum creatinine ≤ 1.5 x upper limit of normal (ULN) , AST or ALT ≤ 2.5 x ULN (≤ 5 x ULN for liver involvement), serum total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for liver involvement)
Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

Presence of any of the following will exclude a patient from enrollment:

Previous treatment for PTCL with immunotherapy or chemotherapy except for short-term corticosteroids (duration of ≤ 8 days) before randomization
Contraindication to any drug contained in the chemotherapy regimen
Previous or current malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast have been effectively controlled) unless the patient has been free of the disease for ≥ 5 years
Primary or secondary central nervous system (CNS) lymphoma involvement or having a history of CNS lymphoma at the time of recruitment
Undergone major surgical procedures within 14 days prior to the first dose of study drug
Significant and uncontrolled cardiovascular disease at screening
Any of the following laboratory abnormalities, except if secondary to the lymphoma:
Absolute neutrophil count (ANC) < 1,000 cells/mm3 (1.0 x 109/L),
Platelet count < 50,000/mm3 (50 x 109/L)
Serum total bilirubin > 2 x ULN, serum ALT or AST > 3.0 x upper limit of normal (ULN), except if investigator believes that the abnormal liver function is caused by the disease
Serum creatinine > 2.0 x ULN, except if investigator believes that the abnormal liver function is caused by the disease
Uncontrolled active systemic fungal, bacterial, viral or other infections
Subjects with HIV positivity
Subjects with active hepatitis B or C (HBs Ag+/HBc Ab+ and HBV DNA>1x103copy/mL; HCV DNA>1x103copy/mL)
Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study.
Other situations that investigators considered inappropriate for enrollment